BHVN
Biohaven Ltd.
$15.15
-0.40
(-2.54%)
Mkt Cap
1.60B
Volume
885,526
52W Range
7.48-18.566
Sector
Healthcare
Beta
3.14
EPS (TTM)
-5.67
P/E Ratio
-1.65
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Biohaven Ltd. operates as a biopharmaceutical firm actively engaged in clinical trials. Its primary objective is to advance innovative treatments for disorders affecting the nervous and immune systems, with the potential to transform current medical interventions.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (738.82M) | (846.42M) | (408.17M) | (570.28M) | (213.80M) | (118.67M) | (528.80M) |
| EPS | -6.86 | -9.28 | -5.73 | -12.75 | -5.97 | -3.31 | -10.91 |
| Free Cash Flow | (610.15M) | (586.50M) | (334.77M) | (338.76M) | (146.78M) | (78.65M) | (379.87M) |
| FCF / Share | -5.67 | -6.43 | -4.70 | -7.57 | -4.10 | -2.20 | -7.83 |
| Operating CF | (609.44M) | (582.45M) | (331.73M) | (297.69M) | (145.84M) | (75.96M) | (377.33M) |
| Total Assets | 451.45M | 615.11M | 513.21M | 661.78M | 142.06M | 111.50M | 344.26M |
| Total Debt | 284.61M | 36.58M | 30.88M | 33.60M | 3.24M | 3.60M | 0 |
| Cash & Equiv | 229.96M | 99.13M | 248.40M | 204.88M | 76.06M | 82.51M | 316.73M |
| Book Value | 52.07M | 423.44M | 427.98M | 538.77M | 34.69M | 16.78M | (7.42M) |
| Return on Equity | -14.19 | -2.00 | -0.95 | -1.06 | -6.16 | -7.07 | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (130.53M) | (145.56M) | (173.44M) | (198.15M) | (221.68M) | (186.84M) | (160.30M) | (319.77M) | (179.50M) | (144.76M) | (102.57M) | (90.35M) |
| EPS | -0.88 | -1.21 | -1.64 | -1.94 | -2.17 | -1.85 | -1.70 | -3.64 | -2.20 | -1.81 | -1.50 | -1.32 |
| Free Cash Flow | (149.92M) | (130.67M) | (145.73M) | (168.17M) | (165.59M) | (170.79M) | (141.89M) | (170.75M) | (103.08M) | (115.35M) | (96.06M) | (44.99M) |
| FCF / Share | -1.02 | -1.09 | -1.38 | -1.64 | -1.62 | -1.69 | -1.50 | -1.95 | -1.26 | -1.44 | -1.41 | -0.66 |
| Operating CF | (149.92M) | (130.66M) | (145.72M) | (167.94M) | (165.12M) | (170.74M) | (141.28M) | (167.80M) | (102.64M) | (114.88M) | (94.81M) | (44.39M) |
| Total Assets | 466.41M | 451.45M | 409.12M | 550.41M | 458.95M | 615.11M | 510.52M | 582.64M | 418.53M | 513.21M | 382.74M | 506.74M |
| Total Debt | 286.18M | 284.61M | 314.18M | 291.56M | 35.51M | 36.58M | 28.99M | 29.74M | 30.53M | 30.88M | 31.57M | 29.11M |
| Cash & Equiv | 273.07M | 229.96M | 184.85M | 165.80M | 98.42M | 99.13M | 84.39M | 239.15M | 182.71M | 248.40M | 111.70M | 147.61M |
| Book Value | 129.50M | 52.07M | (17.16M) | 134.59M | 259.50M | 423.44M | 316.01M | 383.74M | 301.45M | 427.98M | 290.01M | 387.25M |
| Return on Equity | -1.01 | -2.80 | N/A | -1.47 | -0.85 | -0.44 | -0.51 | -0.83 | -0.60 | -0.34 | -0.35 | -0.23 |
BHVN News
Biohaven: Nice Pipeline Momentum, But Its Runway Is A Risk
Biohaven Announces Scientific Leadership Transitions
Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator
Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease
Biohaven: Upgrading To Buy On Protein Degraders Pivotal Study Initiations
Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation
Biohaven: Despite Today's Gains, I Remain Skeptical
Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy